Your browser doesn't support javascript.
loading
Pharmacological interventions to improve sleep in people with Alzheimer's disease: a meta-analysis of randomized controlled trials.
Bedward, Amy; Kaur, Jasmine; Seedat, Sadiyah; Donohue, Holly; Kow, Chia Siang; Rasheed, Muhammad Kamran; Javed, Amaan; Hasan, Syed Shahzad.
Afiliação
  • Bedward A; School of Applied Sciences, University of Huddersfield, Huddersfield, West Yorkshire, UK.
  • Kaur J; School of Applied Sciences, University of Huddersfield, Huddersfield, West Yorkshire, UK.
  • Seedat S; School of Applied Sciences, University of Huddersfield, Huddersfield, West Yorkshire, UK.
  • Donohue H; School of Applied Sciences, University of Huddersfield, Huddersfield, West Yorkshire, UK.
  • Kow CS; School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.
  • Rasheed MK; Department of Pharmacy Practice, College of Pharmacy, Qassim University, Buraydah, Saudi Arabia.
  • Javed A; University College of Medical Sciences, University of Delhi, New Delhi, India.
  • Hasan SS; School of Applied Sciences, University of Huddersfield, Huddersfield, West Yorkshire, UK.
Expert Rev Neurother ; 24(5): 527-539, 2024 May.
Article em En | MEDLINE | ID: mdl-38597219
ABSTRACT

INTRODUCTION:

This systematic review and meta-analysis evaluates the evidence from randomized controlled trials (RCTs) involving pharmacological interventions for improving sleep in people with Alzheimer's disease (AD).

METHODS:

A systematic literature search in eight databases from January 2000 to July 2023 focusing on RCTs that compared a pharmacological intervention with a placebo for enhancing sleep in people with AD. The authors registered the study protocol at Prospero, followed the PRISMA guidelines, and produced the pooled estimates using random-effect or IVhet models.

RESULTS:

Eight different interventions and 29 different sleep outcomes were examined in 14 RCTs included in this review. Eszopiclone positively affected sleep efficiency, as did orexin antagonists. However, there was no difference when melatonin was used. The interventions demonstrated low discontinuation rates and a few adverse drug reactions.

CONCLUSION:

Although melatonin was the most investigated intervention, the evidence for its efficacy is inconclusive. On the other hand, trazodone and orexin receptor antagonists showed promising results; however, more RCTs are needed for definite answers.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto / Doença de Alzheimer / Melatonina Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto / Doença de Alzheimer / Melatonina Idioma: En Ano de publicação: 2024 Tipo de documento: Article